glp-1 pens New Guidelines on Drugs for Obesity Released Decoding GLP-1 Weight Loss Medications

Outcomes The outcome of interest, intestinal obstruction, was identified using ICD-10 diagnosis codes, including obstruction of duodenum (ICD K31.5), paralytic ileus (ICD K56.0), ileus (ICD K56.7), and other specified types of intestinal obstruction (ICD K56.4, K56.6) [15, 16]

A retrospective observational study published in Clinical Nutrition found that nutritional deficiencies were diagnosed in 12.7% of patients within 6 months of starting GLP-1 receptor agonists, and that number climbed to 22.4% within 12 months

doi: 10.1007/s00404-015-3976-7

Within that context, glucagon receptor activation may contribute beneficial effects on energy expenditure, fatty acid oxidation, and hepatic lipid metabolism

Your medical team will closely track your progress, adjust your treatment plan as needed, and provide ongoing support throughout your weight loss journey